glp-1 receptor agonists and cancer risk in adults with obesity show anti-cancer benefits beyond weight loss Glucagon-like peptide-1 receptor agonists compared

While previous generations GLP-1 agonists (liraglutide) have led to weight loss of 5-10% in most cases, semaglutide can lead to weight loss of up to 20%

[DOI] [PubMed] [Google Scholar] 182.Hui H., Farilla L., Merkel P., Perfetti R

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

However, efficacy in these latter indications remains under investigation

Thus, it appeared that proglucagon undergoes a tissue-specific, differential processing leading to the formation of glicentin and oxyntomodulin in the gut and to glucagon plus the N-terminal fragment of glicentin in the pancreas [34,43] (Figure 1)